Krazati (adagrasib tablets - Mirati Therapeutics) — Cigna

Initial criteria

• Patient is age ≥ 18 years
• Patient has KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an approved test
• Patient meets ONE of the following (i or ii): i) Patient has been previously treated with at least one systemic regimen; OR ii) Patient has brain metastases

Approval duration

1 year